Article: Nicotinamide Riboside Prevents Oocyte Quality Loss in Maternal Diabetes: Preclinical Findings

Apr 23, 2025 Diabetes Preclinical Reproductive Health

Nicotinamide Riboside Prevents Oocyte Quality Loss in Maternal Diabetes: Preclinical Findings

Synopsis

Diabetes reduces NAD+ levels in ovaries and oocytes, leading to poor oocyte quality, abnormal spindle formation, excess ROS, and impaired embryo development. In streptozotocin-induced diabetic mice, nicotinamide riboside (NR) supplementation (400 mg/kg/day for 14 days) restored ovarian and oocyte NAD+, improved superovulation, normalized spindle structure, enhanced mitochondrial function, and lowered ROS. These improvements increased fertilization outcomes and early embryo development. The findings indicate that dietary NR supplementation is a promising, noninvasive strategy to protect oocytes from diabetes-related damage and may improve success rates in maternal diabetes and assisted reproductive technologies.

Journal

Reproduction (Cambridge, England)

See Published Study

Cellular Health

Mixed-Mode LC-MS Method Quantifies NAD+ and Its Metabolites: Preclinical Findings

Synopsis Measuring NAD+ and its metabolites is technically difficult because these molecules are highly polar and poorly retained by standard chromatography. This study developed a robust mixed-mo...